Definitions used by the programme

For the purposes of this data collection, these are defined as the total number of patients assessed for the eligibility of tirzepatide (Mounjaro®) for the management of obesity in primary care settings as per the eligibility criteria under the NICE Funding Variation cohorting approach outlined in the interim commissioning guidance. The SNOMED code(s) that will be required to determine the above are as follows.

For the purposes of this data collection, this will be the total number of patients who commenced tirzepatide (Mounjaro®) for the management of obesity, after being assessed in a primary care setting, and are eligible as per the NICE funding variation and initial cohorts outlined in the interim commissioning guidance. This will not include repeat prescriptions / titration. Just those patients initiated tirzepatide (Mounjaro®) in that reporting period.

The SNOMED code(s) that will be required to determine the above are as follows

For the purposes of this data collection, this will be the total number of patients in the reporting period referred to the national wrap around care service who are eligible to be prescribed tirzepatide (Mounjaro®) for the management of obesity in a primary care setting as per the NICE funding variation and initial cohorts outlined in the interim commissioning guidance.

*The number of patients referred to national and or local wraparound care should equal the number of patients prescribed tirzepatide (Mounjaro®) in primary care settings.

For the purposes of this data collection, this will be the total number of patients in the reporting period referred to the local wrap around care service who are eligible to be prescribed tirzepatide (Mounjaro®) for the management of obesity in a primary care setting as per the NICE funding variation and initial cohorts outlined in the interim commissioning guidance.

NHS England will also need to be advised that the ICB is utilising a local arrangement for wraparound care.

* The number of patients referred to national and/or local wraparound care should equal the number of patients prescribed tirzepatide (Mounjaro®) in primary care settings.

The total number of patients in the reporting period who were eligible to be prescribed tirzepatide (Mounjaro®) in primary care settings for the management of obesity as per the NICE funding variation and initial cohorts outlined in the interim commissioning guidance but declined treatment.

The total number of patients in the reporting period who included in an initial eligible cohort but had their prescription of tirzepatide (Mounjaro®) stopped, in a primary care setting.